Advertisement

Polycystic Ovary Syndrome

  • Stavroula A. Paschou
  • Dimitrios G. Goulis
  • Basil C. Tarlatzis
Chapter
Part of the ISGE Series book series (ISGE)

Abstract

Polycystic ovary syndrome (PCOS) is a very common endocrine disorder of the female reproductive life, characterized by chronic anovulation and hyperandrogenism. Women with PCOS present menstrual cycle disturbances and signs of hyperandrogenism, such as hirsutism and acne, while many of them are obese, develop insulin resistance, and manifest metabolic disturbances, such as dyslipidemia, hypertension, and glycemic dysregulation. The purpose of this chapter is to discuss criteria and definition of PCOS, to present current epidemiological data, and to analyze the main hypotheses of its pathophysiology and, furthermore, to discuss the appropriate diagnostic algorithms with employment of clinical examination accompanied with laboratory and/or imaging modalities and to propose causative treatment of various parameters of the syndrome, including metabolic disease, menstrual disturbances, hirsutism, and infertility.

Keywords

Polycystic ovary syndrome Hyperandrogenism Chronic anovulation Pathophysiology Diagnosis Treatment 

References

  1. 1.
    Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.CrossRefGoogle Scholar
  2. 2.
    Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.CrossRefGoogle Scholar
  3. 3.
    Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long-term metabolic consequences. Metabolism. 2017. pii: S0026-0495(17)30274-3;  https://doi.org/10.1016/j.metabol.2017.09.016.CrossRefGoogle Scholar
  4. 4.
    Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO, ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171:P1–29.CrossRefGoogle Scholar
  5. 5.
    Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992. p. 377–84.Google Scholar
  6. 6.
    The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.CrossRefGoogle Scholar
  7. 7.
    Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.CrossRefGoogle Scholar
  8. 8.
    Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK, Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.CrossRefGoogle Scholar
  9. 9.
    Final Report National Institute of Health. Evidence-based methodology workshop on polycystic ovary syndrome. 3–5 Dec. 2012. Executive summary at http://prevention.nih.gov/workshops/2012/pcos/resourc-es.aspx.
  10. 10.
    Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3:103–11.CrossRefGoogle Scholar
  11. 11.
    Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26:251–82.CrossRefGoogle Scholar
  12. 12.
    Zhao H, Lv Y, Li L, Chen ZJ. Genetic studies on polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:56–65.CrossRefGoogle Scholar
  13. 13.
    Sir-Petermann T, Hitchsfeld C, Maliqueo M, Codner E, Echiburú B, Gazitúa R, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod. 2005;20:2122–6.CrossRefGoogle Scholar
  14. 14.
    Paschou SA, Ioannidis D, Vassilatou E, Mizamtsidi M, Panagou M, Lilis D, et al. Birth weight and polycystic ovary syndrome in adult life: is there a causal link? PLoS One. 2015;10:e0122050.CrossRefGoogle Scholar
  15. 15.
    Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005;11:357–74.CrossRefGoogle Scholar
  16. 16.
    Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Chang RJ, Erickson GF. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5321–7.CrossRefGoogle Scholar
  17. 17.
    Coffler MS, Patel K, Dahan MH, Malcom PJ, Kawashima T, Deutsch R, Chang RJ. Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:1742–7.CrossRefGoogle Scholar
  18. 18.
    Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14:367–78.CrossRefGoogle Scholar
  19. 19.
    Catteau-Jonard S, Gallo C, Didier D. Polycystic ovary syndrome: reproductive aspects. In: JAH W, Paul M, Stewart PM, Amiel SA, Davies MJ, editors. Oxford textbook of endocrinology and diabetes. 2nd ed. Oxford: Oxford University Press; 2011.Google Scholar
  20. 20.
    Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007;8:331–42.CrossRefGoogle Scholar
  21. 21.
    Legro RS. Polycystic ovary syndrome: metabolic aspects. In: JAH W, Paul M, Stewart PM, Amiel SA, Davies MJ, editors. Oxford textbook of endocrinology and diabetes. 2nd ed. Oxford: Oxford University Press; 2011.Google Scholar
  22. 22.
    Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf). 1989;30:459–70.CrossRefGoogle Scholar
  23. 23.
    Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril. 1999;71:319–22.CrossRefGoogle Scholar
  24. 24.
    Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2–6.CrossRefGoogle Scholar
  25. 25.
    Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.CrossRefGoogle Scholar
  26. 26.
    Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–30.CrossRefGoogle Scholar
  27. 27.
    Yildiz BO, Azziz R. Hirsutism. In: JAH W, Paul M, Stewart PM, Amiel SA, Davies MJ, editors. Oxford textbook of endocrinology and diabetes. 2nd ed. Oxford: Oxford University Press; 2011.Google Scholar
  28. 28.
    Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210–23.CrossRefGoogle Scholar
  29. 29.
    Yang R, Yang S, Li R, Liu P, Qiao J, Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: a meta-analysis. Reprod Biol Endocrinol. 2016;14:67.CrossRefGoogle Scholar
  30. 30.
    Paschou SA, Palioura E, Ioannidis D, Anagnostis P, Panagiotakou A, Loi V, Karageorgos G, Goulis DG, Vryonidou A. Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS. Endocr Connect. 2017;6:601–6.CrossRefGoogle Scholar
  31. 31.
    Brahimaj A, Muka T, Kavousi M, Laven JS, Dehghan A, Franco OH. Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam study. Diabetologia. 2017;60:98–106.CrossRefGoogle Scholar
  32. 32.
    Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–9.PubMedGoogle Scholar
  33. 33.
    Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63.CrossRefGoogle Scholar
  34. 34.
    Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20:177–91.CrossRefGoogle Scholar
  35. 35.
    Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metabol. 2007;92:405–13.CrossRefGoogle Scholar
  36. 36.
    The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14–24.CrossRefGoogle Scholar
  37. 37.
    Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr. 2006;84:77–87.CrossRefGoogle Scholar
  38. 38.
    Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.CrossRefGoogle Scholar
  39. 39.
    Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De Lorenzo A, Tafuri D, Lombardi G, Colao A, Orio F. Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:1379–84.CrossRefGoogle Scholar
  40. 40.
    Robinson MK. Surgical treatment of obesity-weighing the facts. N Engl J Med. 2009;361:520–1.CrossRefGoogle Scholar
  41. 41.
    Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005;90:6364–9.CrossRefGoogle Scholar
  42. 42.
    Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524–30.PubMedGoogle Scholar
  43. 43.
    Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–46.PubMedGoogle Scholar
  44. 44.
    Barba M, Schünemann HJ, Sperati F, Akl EA, Musicco F, Guyatt G, Muti P. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009;70:661–70.CrossRefGoogle Scholar
  45. 45.
    Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’Keefe M, Ghazzi MN, PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626–32.PubMedGoogle Scholar
  46. 46.
    Lizneva D, Gavrilova-Jordan L, Walker W, Azziz R. Androgen excess: investigations and management. Best Pract Res Clin Obstet Gynaecol. 2016;37:98–118.CrossRefGoogle Scholar
  47. 47.
    Martin KA, Anderson RR, Chang RJ, Ehrmann DA, Lobo RA, Murad MH, Pugeat MM, Rosenfield RL. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233–57.  https://doi.org/10.1210/jc.2018-00241.CrossRefPubMedGoogle Scholar
  48. 48.
    Ruan X, Mueck AO. Oral contraception for women of middle age. Maturitas. 2015;82:266–70.CrossRefGoogle Scholar
  49. 49.
    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–77.CrossRefGoogle Scholar
  50. 50.
    Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:3373–80.CrossRefGoogle Scholar
  51. 51.
    Legro RS, Dodson WC, Kunselman AR, Stetter CM, Kris-Etherton PM, Williams NI, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Diamond MP, Schlaff WD, Casson PR, Christman GM, Barnhart KT, Wright Bates G, Usadi R, Lucidi S, Baker V, Zhang H, Eisenberg E, Coutifaris C, Dokras A. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab. 2016;101:2658–66.CrossRefGoogle Scholar
  52. 52.
    Mutsaerts MAQ, van Oers AM, Groen H, Burggraaff JM, Kuchenbecker WKH, Perquin DAM, Koks CAM, van Golde R, Kaaijk EM, Schierbeek JM, Oosterhuis GJE, Broekmans FJ, Bemelmans WJE, Lambalk CB, Verberg MFG, van der Veen F, Klijn NF, Mercelina PEAM, van Kasteren YM, Nap AW, Brinkhuis EA, Vogel NEA, Mulder RJAB, Gondrie ETCM, de Bruin JP, Sikkema JM, de Greef MHG, ter Bogt NCW, Land JA, Mol BWJ, Hoek A. Randomized trial of a lifestyle program in obese infertile women. N Engl J Med. 2016;374:1942–53.CrossRefGoogle Scholar
  53. 53.
    Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER, Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551–66.CrossRefGoogle Scholar
  54. 54.
    Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007;13:527–37.CrossRefGoogle Scholar
  55. 55.
    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;16(5):CD003053.Google Scholar
  56. 56.
    Requena A, Herrero J, Landeras J, Navarro E, Neyro JL, Salvador C, Tur R, Callejo J, Checa MA, Farre M, Espino JJ, Fabregues F, Grana-Barcia M, Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update. 2008;14:571–82.CrossRefGoogle Scholar
  57. 57.
    Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, for the NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–29.CrossRefGoogle Scholar
  58. 58.
    Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P. Laparoscopic ‘drilling’ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;18(3):CD001122.Google Scholar

Copyright information

© International Society of Gynecological Endocrinology 2019

Authors and Affiliations

  • Stavroula A. Paschou
    • 1
  • Dimitrios G. Goulis
    • 2
  • Basil C. Tarlatzis
    • 3
  1. 1.Division of Endocrinology and Diabetes, “Aghia Sophia” Hospital, Medical SchoolNational and Kapodistrian University of AthensAthensGreece
  2. 2.Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  3. 3.Unit of Human Reproduction, First Department of Obstetrics and Gynecology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece

Personalised recommendations